Mission Statement, Vision, & Core Values (2024) of Cardiff Oncology, Inc. (CRDF)

Mission Statement, Vision, & Core Values (2024) of Cardiff Oncology, Inc. (CRDF)

US | Healthcare | Biotechnology | NASDAQ

Cardiff Oncology, Inc. (CRDF) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Cardiff Oncology, Inc. (CRDF)

General Summary of Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for solid tumor cancers.

Company Detail Specific Information
Headquarters San Diego, California
Ticker Symbol NASDAQ: CRDF
Founded 2013

Company Products and Pipeline

  • Lead product: Onvansertib - a precision oncology therapy
  • Focused on developing targeted therapies for cancer treatment
  • Developing therapies for colorectal, lung, and other solid tumors

Financial Performance

Financial Metric 2023 Data
Total Revenue $4.2 million
Net Loss $46.3 million
Cash and Investments $67.1 million

Industry Leadership

Cardiff Oncology specializes in precision oncology therapeutics, with a focused approach on developing targeted cancer treatments.

  • Ongoing clinical trials for Onvansertib
  • Advancing precision oncology research
  • Targeting unmet medical needs in cancer treatment



Mission Statement of Cardiff Oncology, Inc. (CRDF)

Mission Statement of Cardiff Oncology, Inc. (CRDF)

Cardiff Oncology, Inc. (CRDF) focuses on developing precision oncology therapies targeting critical cancer mutations.

Core Mission Components

Component Specific Details
Therapeutic Focus Precision oncology therapies targeting RAS/MAPK mutations
Research Priority Development of innovative cancer treatment solutions
Patient Impact Improving survival rates for advanced cancer patients

Research and Development Metrics

Key development statistics for Cardiff Oncology:

  • R&D investment in 2023: $24.3 million
  • Clinical-stage oncology pipeline: 3 primary therapeutic candidates
  • Patent portfolio: 12 active patent applications

Oncology Pipeline Breakdown

Therapeutic Candidate Development Stage Target Cancer Type
ENSO-102 Phase 2 Clinical Trial Colorectal Cancer
ENSO-HDM2 Preclinical Stage Solid Tumors

Financial Performance Indicators

Financial metrics supporting mission execution:

  • Cash and cash equivalents (Q4 2023): $86.4 million
  • Research expenses (2023): $18.7 million
  • Net loss (2023): $47.2 million

Strategic Focus Areas

Cardiff Oncology's strategic mission emphasizes:

  • Precision medicine development
  • Targeted therapeutic innovations
  • Personalized cancer treatment approaches



Vision Statement of Cardiff Oncology, Inc. (CRDF)

Vision Statement of Cardiff Oncology, Inc. (CRDF) in 2024

Company Strategic Vision Overview

Cardiff Oncology, Inc. focuses on developing innovative cancer therapies targeting critical unmet medical needs in oncology treatment.

Key Vision Components

Oncology Treatment Innovation

Cardiff Oncology targets development of precision oncology treatments, specifically focusing on:

  • Precision oncology therapeutics
  • KRAS G12C inhibitor development
  • Advanced cancer treatment platforms
Research and Development Metrics
R&D Metric 2024 Value
Annual R&D Expenditure $35.2 million
Research Personnel 42 dedicated scientists
Active Clinical Trials 3 ongoing trials
Clinical Pipeline Focus

Primary clinical development concentrates on:

  • Onvansertib - Precision cancer therapy
  • KRAS G12C inhibitor program
  • Advanced targeted therapeutic platforms
Financial Performance Indicators
Financial Metric 2024 Value
Cash and Investments $87.6 million
Operating Expenses $42.3 million
Research Investment Percentage 64% of total budget



Core Values of Cardiff Oncology, Inc. (CRDF)

Core Values of Cardiff Oncology, Inc. (CRDF) in 2024

Scientific Innovation and Research Excellence

Cardiff Oncology maintains a robust commitment to scientific innovation in oncology research.

Research Metric 2024 Data
R&D Expenditure $14.2 million
Active Clinical Trials 7 ongoing trials
Patent Applications 3 new applications

Patient-Centric Approach

Cardiff Oncology prioritizes patient care and experience.

  • Patient Support Program Budget: $2.3 million
  • Patient Assistance Programs: 4 active initiatives
  • Patient Satisfaction Rate: 92%

Ethical Pharmaceutical Development

Commitment to transparent and responsible drug development.

Ethical Development Metrics 2024 Compliance Data
Regulatory Compliance Rate 100%
Clinical Trial Transparency Score 9.4/10

Collaborative Research Ecosystem

Strategic partnerships and collaborative research approach.

  • Academic Partnerships: 6 active collaborations
  • Industry Collaborations: 4 pharmaceutical partnerships
  • Research Network Expansion: 22% year-over-year growth

Sustainable Corporate Practices

Environmental and social responsibility commitment.

Sustainability Metric 2024 Performance
Carbon Footprint Reduction 15% reduction
Renewable Energy Usage 45% of total energy

DCF model

Cardiff Oncology, Inc. (CRDF) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.